Designing proteins and antibodies that can bind precisely to disease-associated targets is a cornerstone of therapeutics.
Specifically engineered antibodies and therapeutic proteins selectively bind to molecular targets associated with diseases, resulting in treatments that are both more effective and have fewer side-effects compared with traditional therapies.1
Murat Tunaboylu, founder and CEO at Antiverse, reports.